

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Hangauer et al.

Serial No. : 09/482,585


Filed : January 13, 2000


For : A NOVEL METHOD FOR DESIGNING
PROTEIN KINASE INHIBITORSExaminer:
T. PrasthoferArt Unit:
1627Assistant Commissioner for Patents
Washington, D.C. 20231**Box: Non-Fee Amendment**

Sir:

Transmitted herewith is an **Amendment with Appendix A** (6 pages) in the
above-identified application. Also enclosed are:

- ☒ [X] Small entity status is claimed.
- ☒ [X] Paper copy of Sequence Listing (3 pages).
- ☒ [X] Copy of the Sequence Listing in the form of a computer readable 3.5" diskette.
- ☒ [X] Statement in Accordance with 37 CFR §§ 1.82(f) and (g) (1 page).
- ☒ [X] Copy of Notice to Comply.
- ☒ [X] A self-addressed, prepaid postcard for acknowledging receipt.
- ☒ [X] No additional fee is required.
- ☒ [X] The Commissioner is hereby authorized to charge any additional fees or credit
any overpayment to Deposit Account No. 14-1138.

A duplicate copy of this sheet is enclosed.Date: February 28, 2001
Georgia Evans
Registration No. 44,597NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603
Telephone: (716) 263-1672
Facsimile: (716) 263-1600



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/482,585	01/13/00	David G. Hangauer	19226/931 (R-5495)

ENTERED
Nixon Peabody LLP

FEB 06 2001

FILE 19226/931 JAB
DKT Response Due
February 28, 2001

EXAMINER	
Thomas Prasthofer, Ph.D.	
ART UNIT	PAPER NUMBER
1627	6

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

Notice to Comply with Sequence Rules

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Applicant is given ONE MONTH from the mailing date of this communication within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

General Information Regarding Further Correspondence


Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Thomas W. Prasthofer** whose telephone number is (703) 308-4548. The examiner can normally be reached on Monday-Friday, 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jyothsna Venkat can be reached on (703) 308-2439. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-2742.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Thomas Prasthofer, Ph.D. (Art unit 1627)
January 26, 2001

J. Venkat
DR. JYOTHSNA VENKAT PH.D.
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600 0091
SUPERVISORY PATENT EXAMINER
DR. JYOTHSNA VENKAT PH.D.



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/482,585

01/13/00

HANGAUER

D

19226/931 (R)

EXAMINER

HM22/0130

PRASCHOFER, T

ART UNIT

PAPER NUMBER

1627

DATE MAILED:

01/30/01


Michael L. Goldman
Nixon Peabody LLP
Clinton Square
P. O. Box 1051
Rochester NY 14603

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7. Other: _____

Applicant must provide:

- ☒ An initial ~~or substitute~~ computer readable form (CRF) copy of the "Sequence Listing"
- ☒ An initial ~~or substitute~~ paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123
For CRF submission help, call (703) 308-4212
For PatentIn software help, call (703) 308-6856

Please return a copy of this notice with your response.